Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur®), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome. - Regidor,P.A.; Regidor,M.; Kato,K.; Bier,U.W.; Bühler,K.; Schindler,A.E. (Eur J Obstet Gynecol Reprod Biol, 1997)